Physician profile
Corin E Jaynes
NPI 1619217791
$17,158.93
in general payments reported to CMS, 2019-2025
84 companies · $5,164 in 2025
The $5,164 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,370 · 2022: $2,795 · 2023: $2,921 · 2024: $3,909 · 2025: $5,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $1,180 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,639.02 |
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Education | $174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,171.59 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,158.81 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $869.89 | 2021-2025 | Opdivo, Opdualag, Eliquis |
| Janssen Biotech, INC. | $736.22 | 2021-2025 | Erleada, Darzalex, Tecvayli |
| Lilly USA, LLC | $648.63 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals Lp | $610.94 | 2021-2025 | Calquence, Lynparza, Enhertu |
| Pfizer INC. | $609.56 | 2021-2025 | |
| Incyte Corporation | $557.07 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $556.48 | 2021-2025 | Alunbrig, Ninlaro, Iclusig |
| Glaxosmithkline, LLC. | $487.67 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $443.51 | 2021-2025 | Libtayo |
| Amgen INC. | $434.56 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
| Celgene Corporation | $431.61 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $407.76 | 2021-2025 | |
| Eisai INC. | $367.59 | 2021-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $352.28 | 2021-2025 | Padcev |
| Daiichi Sankyo INC. | $338.02 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Genentech USA, INC. | $322.28 | 2021-2025 | Venclexta, Perjeta, Phesgo |
| Abbvie INC. | $308.40 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $287.74 | 2022-2025 | |
| Novocure INC. | $251.37 | 2021-2025 | Optune Lua (Novottf-200t) |
| Servier Pharmaceuticals LLC | $213.40 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $212.62 | 2022-2025 | |
| Adc Therapeutics America, INC. | $209.68 | 2022-2025 | |
| Kite Pharma, INC. | $203.67 | 2021-2025 | Yescarta |
| Acrotech Biopharma INC. | $195.17 | 2021-2025 | Beleodaq |
| Array Biopharma INC | $191.41 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $178.87 | 2021-2025 | |
| Sobi, INC | $177.84 | 2024-2025 | |
| Gilead Sciences, INC. | $156.20 | 2022-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $153.83 | 2021-2024 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $150.49 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $149.16 | 2022-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $137.48 | 2021-2025 | Onivyde |
| Stemline Therapeutics INC. | $133.25 | 2023-2025 | Orserdu, Elzonris |
| Pharmaessentia USA Corporation | $131.68 | 2022-2025 | Besremi |
| G1 Therapeutics, INC. | $124.03 | 2022-2023 | Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.44 | 2021-2025 | Gilotrif |
| Karyopharm Therapeutics INC. | $121.83 | 2021-2024 | Xpovio |
| Beone Medicines USA, INC. | $108.27 | 2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $103.09 | 2021-2024 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Genmab U.S., INC. | $96.60 | 2023-2025 | Epkinly |
| Beigene USA, INC. | $82.23 | 2022-2024 | Brukinsa |
| Ge Healthcare | $75.43 | 2022 | |
| Morphosys, US INC. | $67.89 | 2021-2023 | Monjuvi |
| Deciphera Pharmaceuticals INC. | $65.29 | 2021-2023 | Qinlock |
| Sumitomo Pharma America, INC. | $62.98 | 2023-2024 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $60.47 | 2021-2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $59.93 | 2024 | Cosela |
| Geron Corporation | $49.82 | 2025 | Rytelo |
| Myovant Sciences INC. | $49.16 | 2022 | |
| Adaptive Biotechnologies Corporation | $46.53 | 2022 | |
| Mirati Therapeutics, INC. | $41.70 | 2023 | Krazati |
| Recordati_rare_diseases_inc. | $40.78 | 2023 | Sylvant |
| Legend Biotech USA INC. | $40.59 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $39.87 | 2024-2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $37.88 | 2021-2024 | Givlaari |
| Shield Therapeutics INC | $37.65 | 2024-2025 | |
| Iovance Biotherapeutics, INC. | $35.87 | 2025 | Amtagvi |
| Csl Behring | $35.47 | 2024 | Hemgenix |
| Acceleron Pharma, INC. | $33.72 | 2021 | |
| Emd Serono, INC. | $29.73 | 2022-2023 | Bavencio |
| Exelixis INC. | $29.59 | 2022-2023 | Cabometyx |
| Janssen Pharmaceuticals, INC | $29.42 | 2022 | |
| Eusa Pharma (US) LLC | $27.70 | 2022 | |
| Fresenius Kabi USA, LLC | $27.26 | 2023 | Stimufend |
| Cti Biopharma Corp. | $26.87 | 2022-2023 | Vonjo |
| Immunocore Limited | $25.98 | 2025 | Kimmtrak |
| Tolmar, INC. | $23.37 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $23.37 | 2025 | Rubraca |
| Astellas Pharma US INC | $22.39 | 2025 | Cresemba |
| Azurity Pharmaceuticals, INC. | $20.73 | 2025 | Danziten |
| Tersera Therapeutics LLC | $20.63 | 2025 | Zoladex |
| Medtronic, INC. | $20.62 | 2022 | |
| Dova Pharmaceuticals | $19.80 | 2021 | |
| Agios Pharmaceuticals, INC. | $19.17 | 2022 | |
| Spectrum Pharmaceuticals INC. | $18.02 | 2025 | Rolvedon |
| Kyowa Kirin, INC. | $17.76 | 2025 | |
| Progenics Pharmaceuticals, INC. | $16.83 | 2025 | |
| Caris Mpi, INC. | $14.69 | 2025 | Mi Cancer Seek |
| Mylan Institutional INC. | $14.06 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.80 | 2021 | |
| Secura Bio, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
Kisqali $1,424Keytruda $901Libtayo $320Lynparza $286Opdivo $285Opdualag $284Verzenio $280Jakafi $278Tukysa $257Jaypirca $251Lenvima $225Ibrance $224Ojjaara $222Venclexta $217Sarclisa $216Scemblix $212Zepzelca $210Welireg $210Monjuvi $205Reblozyl $191Vonjo $173Erleada $163Fabhalta $158Darzalex $156Brukinsa $154Tibsovo $149Yescarta $144Calquence $143Tavalisse $138Rezlidhia $138Braftovi $137Nubeqa $135Beleodaq $133Enhertu $133Mektovi $132Epkinly $130Pemazyre $125Tecvayli $118Inqovi $118Lonsurf $118Orserdu $113Pomalyst $110Besremi $110Fotivda $109Lorbrena $108Optune Lua (Novottf-200t) $107Elrexfio $105Imbruvica $100Alunbrig $99.31Cosela $98.19Trodelvy $97.12Jemperli $93.72Retevmo $91.95Adcetris $86.08Injectafer $81.76Zejula $81.43Xofigo $81.34Ninlaro $78.02Pluvicto $77.27Iclusig $77.05Fruzaqla $73.38Padcev $73.15Datroway $72.15Eliquis $70.26Ultomiris $69.91Carvykti $66.15Paxlovid $64.41Orgovyx $62.98Perjeta $62.83Phesgo $62.83Krazati $60.68Zynlonta $59.36Xpovio $56.89Gilotrif $56.37Balversa $55.62Akeega $55.62Lumakras $53.54Inlyta $52.24Rytelo $49.82Tasigna $47.61Zynyz $46.83Rubraca $46.74Bosulif $46.39Voranigo $44.41Onivyde $44.02Tecentriq $42.04Sylvant $40.78Promacta $40.76Empaveli $39.87Accrufer $37.65Stivarga $36.22Amtagvi $35.87Hemgenix $35.47Elahere $34.39Elitek $33.21Cablivi $33.09Enjaymo $33.09Qinlock $31.76Rybrevant $29.47Inluriyo $27.56
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corin Jaynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.